BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sanofi (France) (SAN.PA): U.S. Probes Disclosures to FDA About Patient Response to Plavix


3/11/2013 8:25:31 AM

The U.S. Justice Department is investigating disclosures to the Food and Drug Administration about the variability in patient responses to the blood-thinning drug Plavix, according to Sanofi (SNY), one of the drug's co-marketers. Sanofi became aware of the investigation in June 2012, but disclosed it for the first time in an annual report filed Thursday with the U.S. Securities and Exchange Commission. The French drug maker said it is cooperating with the Justice Department. Sanofi co-markets Plavix, which is used to stave off recurrent heart attacks and strokes, with New York-based Bristol-Myers Squibb Co. (BMY). The anti-clotting drug had worldwide sales of $9.3 billion in 2011, according to IMS Health, before it lost patent protection in 2012, which triggered competition from low-cost generics. Spokesmen for Sanofi and Bristol-Myers declined comment. A Justice Department spokesman couldn't immediately be reached. In 2010, the U.S. Food and Drug Administration added a boxed warning to the prescribing label for Plavix about the potential for reduced effectiveness in a subgroup of patients who metabolize the drug poorly.

Read at Fox News

Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES